Drug Guidance for Subsidy 12/07/2022 Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended aflibercept, bevacizuma... See all × 12/07/2022 Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended aflibercept, bevacizumab reference biologic (Avastin) or ramucirumab for subsidy for treating metastatic colorectal cancer. NRBevacizumab (Avastin) has not been recommended in view of unfavourable cost effectiveness compared with bevacizumab biosimilar (Mvasi) at the price proposed by the manufacturer. NRAflibercept has not been recommended due to low clinical need and unfavourable cost effectiveness compared with Mvasi. NRRamucirumab has not been recommended following a request from the manufacturer to not consider it for subsidy. Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.
Post Marketing Information DHCPL 04/09/2014 Potential risk for medication error between ZALTRAP® (aflibercept, formulated for intravenous use) and EYLEA® (aflibercept, formulated for intravitreal use)
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Zaltrap Infusion, Solution Concentrate 25 mg/mL National University Hospital
INTRAVENOUS Select a brand starting with the letter: Z ZALTRAP CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML [SIN14592P]